Mitomycin intravesicular - UroGen

Drug Profile

Mitomycin intravesicular - UroGen

Alternative Names: MitoGel™; Mitomycin C mixed with TC Gel; Mitomycin C mixed with TC-3 gel; MMC gel; VesiGel™

Latest Information Update: 30 Jun 2017

Price : $50

At a glance

  • Originator TheraCoat
  • Developer UroGen Pharma
  • Class Antineoplastics; Aziridines; Carbamates; Cytostatic antibiotics; Indoles; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Urogenital cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Bladder cancer

Most Recent Events

  • 15 Jun 2017 TheraCoat completes a phase II trial for Bladder cancer (Neoadjuvant therapy) in Israel (NCT02307487)
  • 01 Feb 2017 Phase-III clinical trials in Bladder cancer in USA (Intravesicular) (NCT02793128)
  • 12 Dec 2016 US FDA accepts IND application for mitomycin in Urogenital cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top